A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
A phase 1/2 trial of Pembrolizumab, Intismeran autogene and Enfortumab vedotin in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) is a phase 1/2 interventional study registered as NCT06305767 by Merck Sharp & Dohme LLC, with 230 participants enrolled, started 2024-03-28 and due to reach its primary completion in 2027-04-23. Interventions recorded: Pembrolizumab, Intismeran autogene, Enfortumab Vedotin and Surgery (RC plus PLND).
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Shares Intismeran autogene, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Enfortumab vedotin, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Enfortumab vedotin, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.